{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&q=Hodgkin",
    "query": {
      "q": "Hodgkin",
      "condition": "Lymphoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3781,
    "total_pages": 379,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&q=Hodgkin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T22:40:29.997Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03190928",
      "title": "Clonal Evolution in Follicular Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Follicular Lymphoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2017-07-27",
      "completion_date": "2029-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-07-23T22:40:29.997Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03190928"
    },
    {
      "nct_id": "NCT00475332",
      "title": "Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Iodine I -01 Tositumomab (Bexxar)",
          "type": "DRUG"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2007-09",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2012-02-15",
      "last_synced_at": "2026-07-23T22:40:29.997Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00475332"
    },
    {
      "nct_id": "NCT04191187",
      "title": "Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Biphenotypic Acute Leukemia",
        "Undifferentiated Leukemia",
        "Prolymphocytic Leukemia",
        "Myelodysplastic Syndromes",
        "Chronic Myelogenous Leukemia",
        "Myeloproliferative Neoplasm",
        "Relapsed Large Cell Lymphoma",
        "Mantle Cell Lymphoma",
        "Hodgkin Lymphoma",
        "Burkitt Lymphoma",
        "Relapsed T-Cell Lymphoma",
        "Relapsed Chronic Lymphocytic Leukemia",
        "Relapsed Small Lymphocytic Lymphoma",
        "Relapsed Marginal B-cell Lymphoma",
        "Relapsed Follicular Lymphoma",
        "Lymphoplasmacytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2019-12-06",
      "completion_date": "2024-02-14",
      "has_results": true,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-07-23T22:40:29.997Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04191187"
    },
    {
      "nct_id": "NCT02420795",
      "title": "Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System Lymphoma",
        "Gastric Mantle Cell Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Splenic Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Akt/ERK Inhibitor ONC201",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2015-11-03",
      "completion_date": "2020-11-16",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-07-23T22:40:29.997Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02420795"
    },
    {
      "nct_id": "NCT00498914",
      "title": "Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Large-Cell, Diffuse",
        "Lymphoma, B-Cell Refractory"
      ],
      "interventions": [
        {
          "name": "YM155",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2007-06",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2015-09-04",
      "last_synced_at": "2026-07-23T22:40:29.997Z",
      "location_count": 12,
      "location_summary": "Beverly Hills, California • Palo Alto, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00498914"
    },
    {
      "nct_id": "NCT00324831",
      "title": "GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "autologous immunoglobulin idiotype-KLH conjugate vaccine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "DRUG"
        },
        {
          "name": "vincristine",
          "type": "DRUG"
        },
        {
          "name": "Intervention/procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "antibody therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "biological therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "chemotherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "colony-stimulating factor therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "cytokine therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "monoclonal antibody therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "non-specific immune-modulator therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "therapeutic procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "tumor cell derivative vaccine",
          "type": "PROCEDURE"
        },
        {
          "name": "vaccine therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Favrille",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 480,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-07-23T22:40:29.997Z",
      "location_count": 2,
      "location_summary": "Beverly Hills, California • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324831"
    },
    {
      "nct_id": "NCT07682792",
      "title": "Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mycosis Fungoides/Sezary Syndrome",
        "T-cell Large Granular Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Golidocitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-09-30",
      "completion_date": "2032-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-07-23T22:40:29.997Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07682792"
    },
    {
      "nct_id": "NCT01979536",
      "title": "Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma, ALK-Positive",
        "Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma",
        "Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma",
        "Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 137,
      "start_date": "2013-11-13",
      "completion_date": "2024-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-04-30",
      "last_synced_at": "2026-07-23T22:40:29.997Z",
      "location_count": 154,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01979536"
    },
    {
      "nct_id": "NCT00285428",
      "title": "Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "hA20-humanized anti-CD20 antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2004-09",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-07-23T22:40:29.997Z",
      "location_count": 3,
      "location_summary": "New York, New York • Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00285428"
    },
    {
      "nct_id": "NCT02682667",
      "title": "Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Myeloma",
        "Lymphoma, Non-Hodgkin",
        "Leukemia-Lymphoma, Adult T-Cell",
        "Hodgkin Disease",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 500,
      "start_date": "2016-04-11",
      "completion_date": "2032-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-07-23T22:40:29.997Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02682667"
    }
  ]
}